Altered expression of CD44 and DKK1 in the progression of Barrett’s esophagus to esophageal adenocarcinoma

被引:0
|
作者
T. Darlavoix
W. Seelentag
P. Yan
A. Bachmann
F. T. Bosman
机构
[1] Academic Medical Center,
[2] University of Amsterdam,undefined
[3] Unilabs Lausanne-Cypa,undefined
[4] Laboratory of Cytology and Pathology,undefined
[5] University Institute of Pathology,undefined
[6] University of Lausanne,undefined
来源
Virchows Archiv | 2009年 / 454卷
关键词
Barrett’s esophagus; Esophageal adenocarcinoma; Dysplasia;
D O I
暂无
中图分类号
学科分类号
摘要
Barrett’s esophagus (BE) is an acquired condition in which the normal lining of the esophagus is replaced by intestinal metaplastic epithelium. BE can evolve to esophageal adenocarcinoma (EAC) through low-grade dysplasia (LGD) and high-grade dysplasia (HGD). The only generally accepted marker for increased risk of EAC is the presence of HGD, diagnosed on endoscopic biopsies. More specific markers for the prediction of EAC risk are needed. A tissue microarray was constructed comprising tissue samples from BE, LGD, HGD, and EAC. Marker expression was studied by immunohistochemistry using antibodies against CD44, DKK1, CDX2, COX2, SOX9, OCT1, E-cadherin, and β-catenin. Immunostaining was evaluated semi-quantitatively. CD44 expression decreased in HGD and EAC relative to BE and LGD. DKK1 expression increased in HGD and EAC relative to BE and LDG. CDX2 expression increased in HGD but decreased in EAC. COX2 expression decreased in EAC, and SOX9 expression increased only in the upper crypt epithelial cells in HGD. E-cadherin expression decreased in EAC. Nuclear β-catenin was not significantly different between BE, LGD, and HGD. Loss of CD44 and gain of DKK1 expression characterizes progression from BE and LGD to HGD and EAC, and their altered expression might indicate an increased risk for developing an EAC. This observation warrants inclusion of these immunohistochemically detectable markers in a study with a long patient follow-up.
引用
收藏
页码:629 / 637
页数:8
相关论文
共 50 条
  • [21] Alterations to the Esophageal Microbiome Associated with Progression from Barrett's Esophagus to Esophageal Adenocarcinoma
    Snider, Erik J.
    Compres, Griselda
    Freedberg, Daniel E.
    Khiabanian, Hossein
    Nobel, Yael R.
    Stump, Stephania
    Uhlemann, Anne-Catrin
    Lightdale, Charles J.
    Abrams, Julian A.
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2019, 28 (10) : 1687 - 1693
  • [22] Expression of CD44 in premalignant and malignant Barrett's oesophagus
    Lagorce-Pages, C
    Paraf, F
    Dubois, S
    Belghiti, J
    Fléjou, JF
    HISTOPATHOLOGY, 1998, 32 (01) : 7 - 14
  • [23] Altered expression of CD44 in human prostate cancer during progression
    Nagabhushan, M
    Pretlow, TG
    Guo, YJ
    Amini, SB
    Pretlow, TP
    Sy, MS
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1996, 106 (05) : 647 - 651
  • [24] LAMB1 participates Barrett's esophagus progression to esophageal adenocarcinoma: A bioinformatics study
    Chen, Meng
    Cao, Shuqing
    Zhang, Yujing
    Guo, Chenjie
    Yao, Yao
    Hu, Peiting
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2023, 38 : 61 - 62
  • [25] LAMB1 participates Barrett's esophagus progression to esophageal adenocarcinoma: A bioinformatics study
    Chen, Meng
    Cao, Shuqing
    Zhang, Yujing
    Guo, Chenjie
    Yao, Yao
    Hu, Peiting
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2023, 38 : 61 - 62
  • [26] Altered CD44 expression in endometriosis
    Fan, F
    Tawfik, O
    Iczkowski, K
    Nothnick, W
    Thomas, P
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1999, 112 (04) : 544 - 545
  • [27] Utility of a Biomarker Panel to Predict Progression to Esophageal Adenocarcinoma in Barrett's Esophagus
    Wolf, W. Asher
    Lao-Sirieix, Pierre
    Duits, Lucas C.
    Chak, Amitabh
    Shaheen, Nicholas J.
    Fitzgerald, Rebecca
    Bergman, Jacques J.
    GASTROENTEROLOGY, 2014, 146 (05) : S330 - S330
  • [28] Validation of a biomarker panel in Barrett's esophagus to predict progression to esophageal adenocarcinoma
    Eluri, S.
    Klaver, E.
    Duits, L. C.
    Jackson, S. A.
    Bergman, J. J.
    Shaheen, N. J.
    DISEASES OF THE ESOPHAGUS, 2018, 31 (11)
  • [29] Barrett's Esophagus Length is an Independent Risk Factor for Progression to Esophageal Adenocarcinoma
    Tofani, Christina
    Gandhi, Kunjal
    Spataro, Joseph
    Yoo, Joseph
    Murphy, Megan
    Mohan, Neena
    Daitch, Zachary
    Shah, Apeksha
    Janowski, Raymond
    Dabbish, Noreen
    Keith, Scott
    Kastenberg, David
    Coben, Robert M.
    Cohen, Sidney
    Infantolino, Anthony
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2017, 112 : S172 - S173
  • [30] Chemoprevention in Barrett's esophagus and esophageal adenocarcinoma
    Alkhayyat, Motasem
    Kumar, Prabhat
    Sanaka, Krishna O.
    Thota, Prashanthi N.
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2021, 14